Inovio Pharmaceuticals (NASDAQ:INO) announced its earnings results on Wednesday. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.06, RTT News reports. Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The firm had revenue of $8.80 million during the quarter, compared to the consensus estimate of $9.13 million. During the same quarter in the prior year, the company earned ($0.35) EPS. The firm’s revenue for the quarter was up 3.5% compared to the same quarter last year.
Shares of Inovio Pharmaceuticals (NASDAQ INO) traded down $0.07 on Wednesday, hitting $4.47. The stock had a trading volume of 973,868 shares, compared to its average volume of 1,352,314. Inovio Pharmaceuticals has a fifty-two week low of $3.76 and a fifty-two week high of $9.86. The firm has a market cap of $409.94, a PE ratio of -3.81 and a beta of 2.55.
Several analysts recently weighed in on the company. BidaskClub upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday. Zacks Investment Research upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. ValuEngine downgraded Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. HC Wainwright set a $13.00 price target on Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Friday, January 12th. Finally, Maxim Group cut their price target on Inovio Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, February 15th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $18.80.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.